Pharmacokinetics of Local Anesthetics

Physicochemical Properties - Chemical Keys Unlock Action

• pKa: Acidity constant; typical LA range 7.6-8.9. Governs onset speed.
  • Lower pKa → more non-ionized drug at physiologic pH → faster nerve penetration → quicker onset. 📌 Low pKa = Earlier Start.
• Lipid Solubility: Higher solubility → greater potency (easier membrane passage).
• Protein Binding: Higher binding (mainly to α1-acid glycoprotein) → longer duration of action.
• Ionization: LAs are weak bases. Ionized (cationic) form is active intracellularly; non-ionized form crosses membranes. Governed by Henderson-Hasselbalch: $pH = pKa + log([A⁻]/[HA])$.
• Impact Summary:

  Property	Primary Effect	Clinical Implication
  ↓ pKa	Onset	Faster onset
  ↑ Lipid Solubility	Potency	More potent
  ↑ Protein Binding	Duration	Longer duration

⭐ Local anesthetics with lower pKa values have a faster onset of action because a higher fraction of the drug is in the non-ionized form at physiological pH, allowing for more rapid diffusion across nerve membranes.

Absorption of LAs - Getting into System

• Factors:
  • Site Vascularity: ↑ vascularity → ↑ absorption.
  • Dose: ↑ dose → ↑ absorption.
  • Lipid Solubility: ↑ solubility → ↑ absorption.
  • Vasoconstrictors: Epinephrine (e.g., 1:200,000) ↓ absorption, prolongs action, ↓ toxicity.

    ⭐ Vasoconstrictors (e.g., epinephrine) decrease LA systemic absorption, prolonging anesthesia and reducing toxicity.

• Site Absorption Rate (Fastest → Slowest): 📌 IV TICS EBS: IV > Tracheal > Intercostal > Caudal > Epidural > Brachial Plexus > Sciatic > Subcutaneous.

Distribution of LAs - Spreading the Numbness

• Tissue Perfusion: High perfusion (brain, liver) = rapid uptake.
• Protein Binding: Binds α1-acid glycoprotein (AAG); ↑ binding = ↓ free drug, longer action.
• Lipid Solubility: ↑ lipid solubility = ↑ potency, ↑ duration, ↑ Vd, ↑ protein binding.
• Volume of Distribution (Vd): ↑ with lipid solubility.
• Special Barriers:
  • Placental Transfer: Crosses placenta; fetal risk.
  • Blood-Brain Barrier (BBB) Penetration: Crosses BBB; CNS toxicity risk.

⭐ Highly lipid-soluble local anesthetics generally have a larger volume of distribution (Vd), greater protein binding, and a longer duration of action.

Metabolism of LAs - Breaking It Down

📌 Mnemonic: Esters (one 'i', e.g., Procaine) vs. Amides (two 'i's, e.g., Lidocaine). Articaine: amide with ester linkage.

Key differences in metabolism:

Start["💉 Local Anesthetics
• Pain management• Sodium blockers"]

Route{"🔄 Route?
• Metabolism path• Chemical class"}

EsterEnz["🧪 Ester Enzyme
• Pseudocholinesterase• Plasma location"] EsterSpeed["⚡ Ester Speed
• Rapid hydrolysis• Short duration"] EsterBy["⚠️ Ester Byproduct
• PABA byproduct• High allergy risk"]

AmideEnz["🧪 Amide Enzyme
• Hepatic CYP450• Liver location"] AmideSpeed["⏳ Amide Speed
• Slower clearance• Longer duration"] AmideBy["📦 Amide Byproducts
• Various metabolites• Lower allergy rate"] AmideNote["🩺 Clinical Note
• Liver disease risk• Drug interactions"]

Start --> Route Route -->|Ester LAs| EsterEnz EsterEnz --> EsterSpeed EsterSpeed --> EsterBy

Route -->|Amide LAs| AmideEnz AmideEnz --> AmideSpeed AmideSpeed --> AmideBy AmideBy --> AmideNote

style Start fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style Route fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style EsterEnz fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style EsterSpeed fill:#F6F5F5, stroke:#E7E6E6, stroke-width:1.5px, rx:12, ry:12, color:#525252 style EsterBy fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C style AmideEnz fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style AmideSpeed fill:#F6F5F5, stroke:#E7E6E6, stroke-width:1.5px, rx:12, ry:12, color:#525252 style AmideBy fill:#F6F5F5, stroke:#E7E6E6, stroke-width:1.5px, rx:12, ry:12, color:#525252 style AmideNote fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8

> ⭐ Prilocaine, an amide LA, has a metabolite (o-toluidine) that can cause methemoglobinemia, especially at **high doses**.


## Excretion & Special Populations - Final Exit & Tweaks
*   **Primary Route**: Renal excretion of metabolites and small amounts of unchanged drug.
    -   Urinary pH: Affects ionization; crucial for ion trapping.
    -   Renal function: Impairment ↓ excretion.
    > ⭐ Acidification of urine increases the ionized fraction of local anesthetics (weak bases), thereby enhancing their renal excretion (ion trapping).
*   **Special Populations**:
    -   Renal Disease: ↓ excretion of metabolites & some LAs; risk of toxicity.
    -   Liver Disease: ↓ amide LA metabolism (e.g., lignocaine); esters less affected.
    -   Pregnancy: ↑Vd (Volume of distribution), altered protein binding, ↑cardiac output; may require dose adjustment.
    -   Elderly: ↓ clearance, potentially ↑ sensitivity.
    -   Neonates: Immature metabolic pathways, ↓ Alpha-1-Acid Glycoprotein (AAG) levels (↑ free drug fraction).

##  High‑Yield Points - ⚡ Biggest Takeaways

> *   **Absorption** depends on **vascularity**, **dose**, and **vasoconstrictors** (e.g., epinephrine).
> *   Higher **lipid solubility** means ↑ **potency** and ↑ **duration of action**.
> *   Greater **protein binding** (to AAG) leads to ↑ **duration of action**.
> *   Lower **pKa** results in a **faster onset** (more unionized form at physiological pH).
> *   **Esters** (e.g., Procaine, one 'i') are metabolized by **plasma pseudocholinesterase**; **Amides** (e.g., Lidocaine, two 'i's) by **hepatic enzymes**.
> *   **Systemic toxicity** correlates with **plasma drug levels**; CNS symptoms typically precede cardiotoxicity.
> *   **Vasoconstrictors** (e.g., epinephrine) decrease **systemic absorption**, prolong **anesthetic duration**, and reduce **potential toxicity**.